However, trastuzumab-deruxtecan (targeting HER2 and topoisomerase-I respectively) with nivolumab showed activity in HER2-overexpressing BlCa39, while disitamab-vedotin (which also targets HER2) was granted US-FDA breakthrough-therapy designation for patients with HER2-positive BlCa following platinum-based chemotherapy19,40. The gene discussed is ERBB2; the disease is bladder transitional cell carcinoma.